

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
 Johannes Bijlsma
 Dimitrios Boumpas
 Gerd Burmester
 Mary Crow
 Iain McInnes
 David Pisetsky

Editorial office

Annals of the Rheumatic Diseases
 BMJ Publishing Group Ltd
 BMA House
 Tavistock Square
 London WC1H 9JR, UK
 T: +44 (0)20 7383 6250
 F: +44 (0)20 7383 6668
 E: ard@bmj.com
 Twitter: @ARD_BMJ
 ISSN: 0003-4967 (print)
 ISSN: 1468-2060 (online)
Impact Factor: 12.384

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2017 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorials

- 935** EULAR recommendations for disease management: guidance not guidelines
D S Pisetsky
- 939** Mitochondrial DNA haplogroups and ageing mechanisms in osteoarthritis
A M Valdes, M B Goldring

Criteria

- 942** Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS)
J B Kummerle-Deschner, S Ozen, P N Tyrrell, I Kone-Paut, R Goldbach-Mansky, H Lachmann, N Blank, H M Hoffman, E Weissbarth-Riedel, B Hugel, T Kallinich, M Gattorno, A Gul, N Ter Haar, M Oswald, F Dedeoglu, L Cantarini, S M Benseler

Recommendations

- 948** 2016 update of the EULAR recommendations for the management of early arthritis
B Combe, R Landewe, C I Daien, C Hua, D Aletaha, J M Álvaro-Gracia, M Bakkers, N Brodin, G R Burmester, C Codreanu, R Conway, M Dougados, P Emery, G Ferraccioli, J Fonseca, K Raza, L Silva-Fernández, J S Smolen, D Skingle, Z Szekanez, T K Kvien, A van der Helm-van Mil, R van Vollenhoven

- 960** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

J S Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, M Dougados, J Nam, S Ramiro, M Voshaar, R van Vollenhoven, D Aletaha, M Aringer, M Boers, C D Buckley, F Buttgereit, V Bykerk, M Cardiel, B Combe, M Cutolo, Y van Eijck-Hustings, P Emery, A Finckh, C Gabay, J Gomez-Reino, L Gossec, J-E Gottenberg, J M W Hazes, T Huizinga, M Jani, D Karateev, M Kouloumas, T Kvien, Z Li, X Mariette, I McInnes, E Mysler, P Nash, K Pavelka, G Poór, C Richez, P van Riel, A Rubbert-Roth, K Saag, J da Silva, T Stamm, T Takeuchi, R Westhovens, M de Wit, D van der Heijde

- 978** 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

D van der Heijde, S Ramiro, R Landewé, X Baraliakos, F Van den Bosch, A Sepriano, A Regel, A Ciurea, H Dagfinrud, M Dougados, F van Gaalen, P Gêher, I van der Horst-Bruinsma, R D Inman, M Jongkees, U Kiltz, T K Kvien, P M Machado, H Marzo-Ortega, A Molto, V Navarro-Compán, S Ozgocmen, F M Pimentel-Santos, J Reveille, M Rudwaleit, J Sieper, P Sampaio-Barros, D Wiek, J Braun

Clinical and epidemiological research

- 992** Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials
C Peterfy, V Strand, L Tian, M Østergaard, Y Lu, J DiCarlo, P Countryman, A Deodhar, R Landewé, V K Ranganath, O Troum, P G Conaghan
- 998** Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R Westhovens, P C Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison

- 1009** Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A Kavanaugh, J Kremer, L Ponce, R Cseuz, O V Reshetko, M Stanislavchuk, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset, P Harrison

- 1020** A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis
G R Burmester, I B McInnes, J Kremer, P Miranda, M Korkosz, J Vencovsky, A Rubbert-Roth, E Mysler, M A Sleeman, A Godwood, D Sinibaldi, X Guo, W I White, B Wang, C-Y Wu, P C Ryan, D Close, M E Weinblatt, on behalf of the EARTH EXPLORER 1 study investigators

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
JMG0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1031** Infections and the risk of incident giant cell arteritis: a population-based, case-control study
R L Rhee, P C Grayson, P A Merkel, G Tomasson
- 1036** Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort
A Molto, S Tezenas du Montcel, D Wendling, M Dougados, A Vanier, L Gossec
- 1042** Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium
P Brito-Zerón, N Acar-Denizli, M Zeher, A Rasmussen, R Seror, E Theander, X Li, C Baldini, J-E Gottenberg, D Danda, L Quartuccio, R Priori, G Hernandez-Molina, A A Kruize, V Valim, M Kvarnstrom, D Sene, R Gerli, S Praprotnik, D Isenberg, R Solans, M Rischmueller, S-K Kwok, G Nordmark, Y Suzuki, R Giacomelli, V Devauchelle-Pensec, M Bombardieri, B Hofauer, H Bootsma, J G Brun, G Fraile, S E Carsons, T A Gheita, J Morel, C Vollenweider, F Atzeni, S Retamozo, I F Horvath, K Sivils, T Mandl, P Sandhya, S De Vita, J Sanchez-Guerrero, E van der Heijden, V F M Trevisani, M Wahren-Herlenius, X Mariette, M Ramos-Casals, on behalf of the EULAR-SS Task Force Big Data Consortium
- 1051** Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan
W Fukuda, T Hanyu, M Katayama, S Mizuki, A Okada, M Miyata, Y Handa, M Hayashi, Y Koyama, K Arai, T Kitaori, H Hagiwara, Y Urushidani, T Yamasaki, Y Ikeno, T Suzuki, A Omoto, T Sugitani, S Morita, S Inokuma
- 1057** Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap
D Lacaille, J A Avina-Zubieta, E C Sayre, M Abrahamowicz
- 1064** Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
E E van Daalen, R Rizzo, A Kronbichler, R Wolterbeek, J A Bruijn, D R Jayne, I M Bajema, C Rahmattulla
- 1070** Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
J Braun, X Baraliakos, A Deodhar, D Baeten, J Sieper, P Emery, A Readie, R Martin, S Mpyofu, H B Richards, for the MEASURE 1 study group
- 1078** Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
G R Burmester, E Choy, A Kivitz, A Ogata, M Bao, A Nomura, S Lacey, J Pei, W Reiss, A Pethoe-Schramm, N L Mallalieu, T Wallace, M Michalska, H Birnboeck, K Stubenrauch, M C Genovese
- 1086** Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort
Z Ez-Zaitouni, P A C Bakker, M van Lunteren, I J Berg, R Landewé, M van Oosterhout, M Lorenzin, D van der Heijde, F A van Gaalen
- 1093** Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
S Ramiro, A Sepriano, K Chatzidionysiou, J L Nam, J S Smolen, D van der Heijde, M Dougados, R van Vollenhoven, J W Bijlsma, G R Burmester, M Scholte-Voshaar, L Falzon, R B M Landewé
- 1102** Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
K Chatzidionysiou, S Emamikia, J Nam, S Ramiro, J Smolen, D van der Heijde, M Dougados, J Bijlsma, G Burmester, M Scholte, R van Vollenhoven, R Landewé
- 1108** Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
J L Nam, K Takase-Minegishi, S Ramiro, K Chatzidionysiou, J S Smolen, D van der Heijde, J W Bijlsma, G R Burmester, M Dougados, M Scholte-Voshaar, R van Vollenhoven, R Landewé

Basic and translational research

- 1114** Mitochondrial DNA haplogroups influence the risk of incident knee osteoarthritis in OAI and CHECK cohorts. A meta-analysis and functional study
M Fernández-Moreno, A Soto-Hermida, M E Vázquez-Mosquera, E Cortés-Pereira, S Relación, T Hermida-Gómez, S Pétega, N Oreiro-Villar, C Fernández-López, R Garesse, F J Blanco, I Rego-Pérez

1123 Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis

F Ciccia, G Guggino, A Rizzo, R Alessandro, M M Luchetti, S Milling, L Saieva, H Cypers, T Siampone, P Di Benedetto, A Gabrielli, A Fasano, D Elewaut, G Triolo

1133 Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages

C Maier, A Ramming, C Bergmann, R Weinkam, N Kittan, G Schett, J H W Distler, C Beyer

1142 Knee and hip intra-articular adipose tissues (IAATs) compared with autologous subcutaneous adipose tissue: a specific phenotype for a central player in osteoarthritis

F Eymard, A Pigenet, D Citadelle, J Tordjman, L Foucher, C Rose, C-H Flouzat Lachamiette, C Rouault, K Clément, F Berenbaum, X Chevalier, X Houard

1150 Transethnic meta-analysis identifies *GSDMA* and *PRDM1* as susceptibility genes to systemic sclerosis

C Terao, T Kawaguchi, P Dieude, J Varga, M Kuwana, M Hudson, Y Kawaguchi, M Matucci-Cerinic, K Ohmura, G Riemekasten, A Kawasaki, P Airo, T Horita, A Oka, E Hachulla, H Yoshifuji, P Caramaschi, N Hunzelmann, M Baron, T Atsumi, P Hassoun, T Torii, M Takahashi, Y Tabara, M Shimizu, A Tochimoto, N Ayuzawa, H Yanagida, H Furukawa, S Tohma, M Hasegawa, M Fujimoto, O Ishikawa, T Yamamoto, D Goto, Y Asano, M Jimin, H Endo, H Takahashi, K Takehara, S Sato, H Ihn, S Raychaudhuri, K Liao, P Gregersen, N Tsuchiya, V Ricciari, I Melchers, G Valentini, A Cauvet, M Martinez, T Mimori, F Matsuda, Y Allanore

Electronic pages

Correspondence

e12 Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!

K F Baker, A G Pratt, B Thompson, J D Isaacs

e13 Response to: 'Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!' by Baker *et al*

M Boers

e14 Identifying arthralgia suspicious for progression to rheumatoid arthritis

K Mankia, J Nam, P Emery

e15 Appropriate use of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

A H M van der Helm-van Mil, R B M Landewé